Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORMD-0801 Effect on Endogenous Glucose Production in T2DM
NCT04564846Phase 2Completed
- Sponsor
- Oramed Pharmaceuticals Inc.
- Start
- Nov 2020
- Primary completion
- Jun 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing ORMD-0801 with Placebo (2 arms). Primary endpoint: Area Under the Curve (AUC(0-16)) of Endogenous Glucose Production at Day 28. Started Nov 2020; status: completed.
02
Drugs
ORMD-0801
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04564846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564846.